DUBLIN–(BUSINESS WIRE)–The “Stroke – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report provides an overview of the Stroke (Cardiovascular) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 13, 33, 24, 1, 3, 122, 17 and 2 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 31 and 5 molecules, respectively.
Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
- Acorda Therapeutics Inc
- Acticor Biotech SAS
- Addex Therapeutics Ltd
- advanceCor GmbH
- AegisCN LLC
- Aegle Therapeutics Corp
- Affibody AB
- Allife Medical Science and Technology Co Ltd
- Allosteros Therapeutics Inc
- Amarantus Bioscience Holdings Inc
- Anavex Life Sciences Corp
- Ankasa Regenerative Therapeutics Inc
- Annovis Bio Inc
- AntiRadical Therapeutics LLC
- Antoxis Ltd
- Apellis Pharmaceuticals Inc
- Aposcience AG
- APT Therapeutics Inc
- AptaTargets SL
- Aranda Pharma Ltd
- AriBio
- ArmaGen Inc
- Aronora Inc
- Artelo Biosciences Inc
- ArunA Biomedical Inc
- Asta Pharmaceuticals Co Ltd
- AstraZeneca Plc
- Athersys Inc
- Avilex Pharma ApS
- Axolo Pharma Inc
- Band Therapeutics LLC
- Beijing Yinfeng Dingcheng Bioengineering Co Ltd
- BioAxone BioSciences Inc
- Biogen Inc
- Boehringer Ingelheim International GmbH
- Brain-Gen LLC
- Bristol-Myers Squibb Co
- CardioVascular BioTherapeutics Inc
- Celltrion Inc
- Cenyx Biotech Inc
- Cerebrum Therapeutics Inc
- CHA Bio & Diostech Co Ltd
- China Resources Emde Biological Pharmaceutical Co Ltd
- Cogentis Therapeutics Inc
- CohBar Inc
- Constant Therapeutics LLC
- CSPC Pharmaceutical Group Ltd
- Curacle Co Ltd
- CuroNZ Ltd
- Daewoong Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- Deha Pharmaceutical LLC
- DiaMedica Therapeutics Inc
- Diffusion Pharmaceuticals Inc
- Edvince AB
- EIP Pharma LLC
- Epigen Biosciences Inc
- Epygen Biotech Pvt Ltd
- Ever Supreme Bio Technology Co Ltd
- Evgen Pharma Plc
- eXithera Pharmaceuticals Inc
- Exscien Corp
- F. Hoffmann-La Roche Ltd
- Fortuna Fix Inc
- Freeox Biotech SL
- Fujifilm Toyama Chemical Co Ltd
- GABA Therapeutics Inc
- Genervon Biopharmaceuticals LLC
- Glialogix Inc
- Glucox Biotech AB
- GNT Pharma Co Ltd
- Guangzhou Cellprotek Pharmaceutical Co Ltd
- Guangzhou Magpie Pharmaceutical Co Ltd
- Guangzhou Recomgen Biotech Co Ltd
- Guangzhou-Sheng Jian Chi Pharmaceutical Co Ltd
- Gwoxi Stem Cell Applied Technology Co Ltd
- Hefei Industrial Pharmaceutical Institute Co Ltd
- Hibernaid Inc
- Hillhurst Biopharmaceuticals Inc
- Hope Biosciences LLC
- HSRx Group
- Immunwork Inc
- Instituto Biomar SA
- International Stem Cell Corp
- JCR Pharmaceuticals Co Ltd
- Jeil Pharmaceutical Co Ltd
- Jiangsu Ouwei Pharmaceutical Co Ltd
- JT Pharmaceuticals Inc
- Kai Nuo Bio Sci Co Ltd
- Kyoto Drug Discovery & Development Co Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/l31y2p
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900